CSL Behring announced that the FDA has granted orphan drug designation for its recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) for the treatment and prophylaxis of bleeding episodes in patients with congenital factor IX deficiency (hemophilia B).
SIGN IN WITH ONE OF YOUR SOCIAL ACCOUNTS
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH ONE OF YOUR SOCIAL ACCOUNTS
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a password reset link.
ENTER NEW PASSWORD